Current Research Limitations Most clinical studies on GHK-Cu involve: Topical formulations In vitro research Animal models Systemic (non-injectable) delivery There is insufficient evidence in peer-reviewed literature to support: standardized injection techniques validated injectable dosing regimens long-term safety or efficacy data for injectable use As a result, clinicians should approach injectable discussions with caution and rely on evidence-based peptide education rather than anecdotal protocols
Some research suggests that hyperhomocysteinaemia may contribute to endothelial dysfunction and low-grade systemic inflammation, though a direct link to joint pain remains unproven
In the CNS, A is released from neurons into brain interstitial fluid (ISF)
Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women
Some patients report mild side effects such as nausea, headaches, fatigue, dizziness, or injection site irritation
It is a direct and vital participant in the TCA cycle and OXPHOS
